Registered title, quoted from ClinicalTrials.gov
Safety and Efficacy Study of NGGT003 in Hemophilia A Patients
An open trial on haemophilia A, registered on ClinicalTrials.gov. Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06238908, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 3
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (3 points)Hide the checklist
18 years to Not stated; sex: men only
Registered eligibility fields
Positive for hepatitis B surface antigen, hepatitis C, human immunodeficiency virus (HIV),syphilis test;
Exclusion criterion 1
Willing to use effective contraceptive methods within 52 weeks after administration.
Inclusion criterion 11
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06238908, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntarily sign the informed consent form;
- Male, age ≥18 years old;
- Diagnosed with hemophilia A according to the "Guidelines for Diagnosis and Treatment of Hemophilia A (2022 Edition)", and the endogenous FVIII activity level was <1 IU/dL (<1%);
- The exposure days (EDs) of treatment with any recombinant or plasma-derived FVIII product were ≥150 days;
- Anti-AAV neutralizing antibody titer ≤1:5, binding antibody titer ≤1:100;
- Bleeding events and/or FVIII product injections have occurred within 12 weeks before screening;
- No history of allergy to FVIII products;
- FVIII inhibitor titer﹤0.6BU/mL;
- Commitment to use other drugs during the study requires the consent of the investigator;
- Willing and able to comply with study procedures and requirements;
- Willing to use effective contraceptive methods within 52 weeks after administration.
Exclusion Criteria:
- Positive for hepatitis B surface antigen, hepatitis C, human immunodeficiency virus (HIV),syphilis test;
- Clinically significant abnormalities in liver function test: alanine aminotransferase (ALT) >1.5 × upper limit of normal (ULN) and/or aspartate aminotransferase (AST) >1.5× ULN;TBil)>1.5×ULN;Serum creatinine (Scr) >1.5×ULN; hemoglobin <110g/L, platelets <10e9/L;
- History of being positive for FVIII inhibitors;
- Have other bleeding factors except hemophilia;
- Plan major surgery within 52 weeks;
- Have contraindications to glucocorticoid, including but not limited to allergy to glucocorticoids, epilepsy, new unhealed fractures, in trauma repair period, uncontrolled infection, severe osteoporosis, etc, which assessed and determined by the investigators;
- History of allergy to human albumin;
- Have serious diseases or active infections in cardiovascular, respiratory, digestive tract, endocrine, renal, blood, nervous, mental and other systems before screening;
- With hepatitis, cirrhosis, liver cancer or other major liver diseases;
- History of malignant tumors;
- Abnormal and clinical significant vital signs, physical examination, laboratory examination or other related examination results during the screen, which are not suitable for trial according to the investigator;
- Previous gene therapy treatment;
- Participation in any other clinical trial before the screening and have taken medication within four weeks or five half-lives of the study drug;
- Any other condition that may not be appropriate for the study in the opinion of the investigator.
Quoted from ClinicalTrials.gov, NCT06238908, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06238908, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.